PhoenixBio Co., Ltd. (JP:6190)
:6190
Want to see JP:6190 full AI Analyst Report?
6190 Stock Chart & Stats
¥484.00
¥9.00(2.79%)
At close: 4:00 PM EST
¥484.00
¥9.00(2.79%)
Day’s Range― - ―
52-Week Range¥315.00 - ¥724.00
Previous CloseN/A
Volume3.50K
Average Volume (3M)360.67K
Market Cap
¥1.78B
Enterprise Value¥1.16B
Total Cash (Recent Filing)¥1.04B
Total Debt (Recent Filing)¥503.59M
Price to Earnings (P/E)6.1
Beta0.54
Next Earnings
May 15, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)19.91
Shares Outstanding4,076,933
10 Day Avg. Volume91,460
30 Day Avg. Volume360,670
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.09
Price to Sales (P/S)0.97
P/FCF Ratio-15.84
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Defensible Niche Business ModelPhoenixBio's core business of supplying specialized disease-model animals and integrated research support targets persistent needs in drug discovery and biomedical R&D. This creates recurring, mission-critical demand from pharma and institutes and supports durable customer relationships and revenue visibility.
Healthy Equity Base And Moderate LeverageA relatively stable equity base and moderate debt levels provide financial flexibility. This reduces refinancing risk, preserves access to capital for operational fixes or investment, and gives management time to restore cash generation without immediate solvency pressure.
Historically Strong Gross MarginsConsistently strong historical gross margins suggest product-level pricing power or efficient variable-cost operations in animal production. If revenue trends stabilize, these margins provide an operating leverage opportunity to return to profitability by controlling fixed costs and scaling existing operations.
Bears Say
Negative Operating Cash FlowSustained negative operating cash flow indicates PhoenixBio struggles to convert activities into cash. That constrains reinvestment in facilities, model development, and service capacity, and increases reliance on external financing which can dilute shareholders or raise funding costs over the medium term.
Negative EBIT And EBITDA MarginsReported negative operating and EBITDA margins in 2025 reflect structural profitability pressure from either weakened revenue or elevated fixed/SG&A costs. Prolonged margin deficits undermine the company's ability to self-fund growth and force hard choices on cost reductions or strategic shifts.
Declining Revenue TrendA material revenue decline in 2025 reduces scale benefits and weakens the economics of breeding, maintenance, and service operations. Shrinking top-line volume risks higher per-unit costs, undermines margin recovery, and limits resources for product development and customer retention initiatives.
6190 FAQ
What was PhoenixBio Co., Ltd.’s price range in the past 12 months?
PhoenixBio Co., Ltd. lowest stock price was ¥315.00 and its highest was ¥724.00 in the past 12 months.
What is PhoenixBio Co., Ltd.’s market cap?
PhoenixBio Co., Ltd.’s market cap is ¥1.78B.
When is PhoenixBio Co., Ltd.’s upcoming earnings report date?
PhoenixBio Co., Ltd.’s upcoming earnings report date is May 15, 2026 which is in 12 days.
How were PhoenixBio Co., Ltd.’s earnings last quarter?
PhoenixBio Co., Ltd. released its earnings results on Feb 13, 2026. The company reported ¥19.91 earnings per share for the quarter, beating the consensus estimate of N/A by ¥19.91.
Is PhoenixBio Co., Ltd. overvalued?
According to Wall Street analysts PhoenixBio Co., Ltd.’s price is currently Overvalued.
Does PhoenixBio Co., Ltd. pay dividends?
PhoenixBio Co., Ltd. does not currently pay dividends.
What is PhoenixBio Co., Ltd.’s EPS estimate?
PhoenixBio Co., Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does PhoenixBio Co., Ltd. have?
PhoenixBio Co., Ltd. has 4,076,933 shares outstanding.
What happened to PhoenixBio Co., Ltd.’s price movement after its last earnings report?
PhoenixBio Co., Ltd. reported an EPS of ¥19.91 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -3.112%.
Which hedge fund is a major shareholder of PhoenixBio Co., Ltd.?
Currently, no hedge funds are holding shares in JP:6190
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
PhoenixBio Co., Ltd.
PhoenixBio Co., Ltd. provides contract study services for drug discovery and development primarily in Japan. The company uses PXB-mouse, a chimeric mouse with a humanized liver for use in drug development experiments; and in vitro studies using fresh human hepatocytes taken from PXB-cells. The chimeric mouse model with a humanized liver is used for in vivo studies in gene therapeutics, NASH/NAFLD drug development programs, anti-viral therapeutic tests, DMPK/toxicity studies, and custom transplantations. The company was founded in 2002 and is headquartered in Higashihiroshima, Japan.
Technical Analysis
Trans Genic Inc.
―
Takara Bio Inc.
―
ReproCELL Inc.
―
Japan Tissue Engineering Co., Ltd.
―
CellSeed Inc.
―